Emerging role of N-myc downstream-regulated gene 2 (NDRG2) in cancer

Wei Hu; Chongxi Fan; Peng Jiang; Zhiqiang Ma; Xiaolong Yan; Shouyin Di; Shuai Jiang; Tian Li; Yedong Cheng; Yang Yang

doi:10.18632/oncotarget.6228

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Emerging role of N-myc downstream-regulated gene 2 (NDRG2) in cancer

Wei Hu, Chongxi Fan, Peng Jiang, Zhiqiang Ma, Xiaolong Yan, Shouyin Di, Shuai Jiang, Tian Li, Yedong Cheng and Yang Yang _

PDF | HTML | How to cite

Oncotarget. 2016; 7:209-223. https://doi.org/10.18632/oncotarget.6228

Metrics: PDF 2965 views | HTML 3837 views | ?

Abstract

Wei Hu1,*, Chongxi Fan2,*, Peng Jiang3,*, Zhiqiang Ma2, Xiaolong Yan2, Shouyin Di2, Shuai Jiang4, Tian Li1, Yedong Cheng3 and Yang Yang1

1 Department of Biomedical Engineering, The Fourth Military Medical University, Xi’an, China

2 Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi’an, China

3 Department of Orthopaedics, The 82th Hospital of PLA, Huaian, China

4 Department of Aerospace Medicine, The Fourth Military Medical University, Xi’an, China

* These authors have contributed equally to this work

Correspondence to:

Yang Yang, email:

Yedong Cheng, email:

Keywords: N-myc downstream-regulated gene 2, cancer, pathological processes, molecular pathways

Received: August 10, 2015 Accepted: October 06, 2015 Published: October 25, 2015

Abstract

N-myc downstream-regulated gene 2 (NDRG2) is a tumor suppressor and cell stress-related gene. NDRG2 is associated with tumor incidence, progression, and metastasis. NDRG2 regulates tumor-associated genes and is regulated by multiple conditions, treatments, and protein/RNA entities, including hyperthermia, trichostatin A and 5-aza-2’-deoxycytidine, which are promising potential cancer therapeutics. In this review, we discuss the expression as well as the clinical and pathological significance of NDRG2 in cancer. The pathological processes and molecular pathways regulated by NDRG2 are also summarized. Moreover, mechanisms for increasing NDRG2 expression in tumors and the potential directions of future NDRG2 research are discussed. The information reviewed here should assist in experimental design and increase the potential of NDRG2 as a therapeutic target for cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6228

Publication Alerts

Reviews:

Emerging role of N-myc downstream-regulated gene 2 (NDRG2) in cancer

Abstract